IFA 2016 is fast approaching, and as with many tech trade shows, companies are jumping farther and farther out with their announcements. LG, for example, has just announced that it will debut not one, ...
Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...
Tomas Franzese is a News Editor at DualShockers, writing a variety of reviews and shedding light on upcoming games for both PC and consoles. While he has been a gamer most of his life, he began ...
Four years ago, Bristol-Myers Squibb paid $1.85 billion upfront to claim rights to Nektar's bempegaldesleukin, setting it up to be companion drug to its cancer immunotherapy Opdivo. Now, that hope is ...
Global networking brand Tenda has released a new product designed to get your home devices online with a minimum of fuss, no matter where they may be inside your house. Tenda started out in China in ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anji Pharmaceuticals, Inc. (“Anji” or “the Company”) today announced the acquisition of global development rights for a novel delayed-release formulation of ...
Eli Lilly was hit with its second big pipeline setback in two days as the big pharma company announced that its once-promising Type 1 diabetes drug teplizumab had flunked a Phase III study and that ...
The Legend of Heroes: Kuro no Kiseki is now available for PC via Steam in Japanese, publisher NIS America and developers Falcom and PH3 announced. The previously released Steam version version, ...
The sudden halt of this Phase III, though, couldn't have come as a complete surprise. The treatment had failed its first Phase III, where the primary endpoint was geared to median time-to-treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback